Idera Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Aceragen

04/08/2021 12:04

* Idera Pharmaceuticals Inc  IDRA.OQ   IDRA.O  is expected
to show a no change in quarterly revenue when it reports
results on August 6 (estimated). 
​* Refinitiv's mean analyst estimate for Idera Pharmaceuticals
Inc is for a loss of 18 cents per share. For the same quarter
last year, the company reported a loss of 72 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Idera
Pharmaceuticals Inc is $1​, about 11% below​ its last closing
price of $1.11. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.22       -0.21      -0.14     Beat    34.9
 Dec. 31 2020  -0.21       -0.23      -2.11     Missed  -830.9
 Sep. 30 2020  -0.22       -0.22      -0.59     Missed  -168.2
                                                        ​
 Jun. 30 2020  -0.39       -0.39      -0.72     Missed  -82.3
 Mar.          -0.40​      -0.41      -0.43     Missed  -5.4​
 31​ 2020​                                              
 Dec. 31 2019  -0.39       -0.35      -1.76     Missed  -400.5
                                                        ​
 Sep. 30 2019  -0.46       -0.46      -0.39     Beat    16.1
 Jun. 30 2019  -0.42       -0.42      -0.39     Beat    7.6
 This summary was machine generated August 4 at 11:04 GMT.  All
figures in US dollars unless otherwise stated